FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCEL-SCI Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CVM
CEL-SCI Corporation Stock AnalysisComprehensive stock analysis for CEL-SCI Corporation (CVM) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCVM
CVM
CEL-SCI Corporation
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CVM
  1. Home
  2. Stocks
  3. CEL-SCI Corporation

CEL-SCI Corporation

🇺🇸CVM•AMEX

CEL-SCI Corporation

🇺🇸CVM•AMEX
Market cap
$29.20M
Sentiment

Your view on CVM

Mkt Cap
$29.20M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About CEL-SCI Corporation

Industry
Biotechnology
Sector
Healthcare
CEO
Geert R. Kersten
Headquarters
8229 Boone Boulevard, Vienna, VA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Geert R. Kersten
Headquarters
8229 Boone Boulevard, Vienna, VA, US
Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer.

Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus.

CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for CEL-SCI Corporation from FRC's valuation model, read against the market price. CVM last traded at $1.66; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for CEL-SCI Corporation. Starting points for CEL-SCI Corporation: EPS -$1.87, beta 0.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for CEL-SCI Corporation. CEL-SCI Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for CEL-SCI Corporation. Trailing twelve-month EPS for CEL-SCI Corporation stands at -$1.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 17, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Analyst Ratings

Buy6 ratings
  • Strong Buy0
  • Buy6
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrMar 2011Next QtrMar 2013Current YearFY Sep 2016Next YearFY Sep 2017
Avg. estimate-$11.00-$5.00-$217.50-$34.20
Low estimate-$13.20-$6.00-$217.50-$34.20
High estimate-$8.80-$4.00-$217.50-$34.20
No. of analysts131011
Year-ago EPS————
Growth————

Revenue Estimate

RevenueCurrent QtrMar 2011Next QtrMar 2013Current YearFY Sep 2016Next YearFY Sep 2017
Avg. estimate$48196.00$30000.00$1.00M$100000.00
Low estimate$38556.00$24000.00$1.00M$100000.00
High estimate$57835.00$36000.00$1.00M$100000.00
No. of analysts131011
Year-ago revenue————
Growth————
Recent analyst actions9 rating and price-target changes, latest Jul 12, 2023 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 17, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for CEL-SCI Corporation. CEL-SCI Corporation has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CVM17 companies · 4 funds
Compare CVM with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ALGSAligos Therapeutics, Inc.Biotechnology$10M
  • BRNSBarinthus Biotherapeutics plcBiotechnology$30M
  • INMBINmune Bio, Inc.Biotechnology$29M
  • OKUROnKure Therapeutics, Inc.Biotechnology$111M
  • PDSBPDS Biotechnology CorporationBiotechnology$52M

More Biotechnology companies

  • ACADACADIA Pharmaceuticals Inc.NASDAQ$3.2B
  • ACETAdicet Bio, Inc.NASDAQ$26M
  • ACHFFArch Biopartners Inc.OTC$41M
  • ACHVAchieve Life Sciences, Inc.NASDAQ$698M
  • ACIUAC Immune S.A.NASDAQ$217M
  • ACOGAlpha Cognition Inc. Common StockNASDAQ$129M
  • ACR.AXAcrux LimitedASX
  • ACRSAclaris Therapeutics, Inc.NASDAQ$622M
  • ACRVAcrivon Therapeutics, Inc. Common StockNASDAQ$62M
  • ACTUActuate Therapeutics IncNASDAQ$7M
  • ACUTAccustem Sciences Inc.OTC$7M
  • ACW.AXActinogen Medical LimitedASX

ETFs holding CEL-SCI Corporation

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%

Largest holders first, then the funds most concentrated in CVM.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold CEL-SCI Corporation, and how their positions are changing. At a $29.2M market value, institutional positions materially move CEL-SCI Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by CEL-SCI Corporation executives and directors. Shares of CEL-SCI Corporation have traded between $1.98 and $32.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for CEL-SCI Corporation. Coverage tracks CEL-SCI Corporation within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of CEL-SCI Corporation.

CVM Analysis
Weak
Past1
Growth2
Health3
Profit1
Value1

News

Latest Market News